The Prevalence of the Potential Drug-Drug Interactions Involving Anticancer Drugs in China: A Retrospective Study
Background: To survey the prevalence of potential drug-drug interactions (DDIs) between anticancer drugs and non-anticancer drugs and evaluate the risk factors associated with these drug-drug interactions in China.
Methods: All discharged patients in the Department of Oncology were collected from Jun to Dec in 2016 with the Hospital Information System of the Chinese people’s Liberation Army General Hospital. Drugs were screened for interactions by Micromedex solutions database. Descriptive statistics were generated and logistic regression was used to identify the associated factors.
Results: Among 6578 eligible patients, 1979 potential drug interactions were found in 1830 patients (27.82%). The most common drug-drug interaction was cisplatin and furosemide. Erlotinib was most likely to interact with various non-anticancer drugs. Most interactions were classified as pharmacodynamics (71.60%), major severity (97.02%) and were supported by fair documentation evidence (86.21%). In multivariate analysis, increasing number of medications, lung cancer and patients with stage IV had a higher risk for potential drug-drug interactions.
Conclusion: Potential drug-drug interactions between antineoplastic drugs and non-antineoplastic drugs occur frequently in cancer patients of Chinese hospitals. Doctors should fully consider potential risk associated with DDIs. Further research should be performed to evaluate real clinical significance of these drug-drug interactions.
2. Becker ML, Kallewaard M, Caspers PW, et al (2007). Hospitalisations and emergency department visits due to drug drug inter-actions: a literature review. Pharmacoepidemi-ol Drug Saf, 16(6):641-51.
3. Janković SM, Pejčić AV, Milosavljević MN, et al (2018). Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care, 43:1-6.
4. Moura CS, Acurcio FA, Belo NO (2009). Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci, 12(3):266-72.
5. Blower P, de Wit R, Goodin S, et al (2005). Drug-drug interactions in oncology: why are they important and can they be min-imized? Crit Rev Oncol Hematol, 55(2): 117–42.
6. Beijnen JH, Schellens JH (2004). Drug inter-actions in oncology. Lancet Oncol, 5(8):489–96.
7. Shiver MB, Hall LA, Conner KB, et al (2014). Cutaneous erosions: a herald for impending pancytopenia in methotrexate toxicity. Dermatol Online J, 20(7): 13030/qt46k975h8.
8. 8.Gass-Jégu F, Gschwend A, Gairard-Dory AC, et al (2016). Gastrointestinal perfora-tions in patients treated with erlotinib: A report of two cases with fatal outcome and literature review. Lung Cancer, 99:76-8.
9. Riechelmann RP, Zimmermann C, Chin SN, et al (2008). Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage, 35(5):535-43.
10. Ko Y, Tan SL, Chan A, et al (2012). Preva-lence of the Coprescription of Clinically Important Interacting Drug Combina-tions Involving Oral Anticancer Agents in Singapore: A Retrospective Database Study. Clin Ther, 34(8):1696-704.
11. Mouzon A, Kerger J, D'Hondt L, et al (2013). Potential interactions with anti-cancer agents: a cross-sectional study. Chemotherapy, 59(2):85-92.
12. Buajordet I, Ebbesen J, Erikssen J, et al (2001). Fatal adverse drug events: the par-adox of drug treatment. J Intern Med, 250(4):327–41.
13. Patel RI, Beckett RD (2016). Evaluation of resources for analyzing drug interactions. J Med Libr Assoc, 104(4):290-5.
14. Peppercorn JM, Smith TJ, Helft PR, et al (2011). American society of clinical on-cology statement: toward individualized care for patients with advanced cancer. J Clin Oncol, 29(6):755-60.
15. 15.Tokito T, Murakami H, Mori K, et al (2015). Implementation status and ex-planatory analysis of early advance care planning for Stage IV non-small cell lung cancer patients. Jpn J Clin Oncol, 45(3):261-6.
16. 16.Malin JL, O'Neill SM, Asch SM, et al (2011). Quality of supportive care for pa-tients with advanced cancer in a VA med-ical center. J Palliat Med, 14(5):573-7.
17. Temel JS1, Greer JA, Muzikansky A, et al (2010). Early palliative care for patients with metastatic non-small-cell lung can-cer. N Engl J Med, 363(8):733-42.
18. Cornelison TL, Reed E (1993). Nephrotoxi-city and hydration man cisplatin, car-boplatin, and ormaplatin. Gynecol Oncol, 50(2):147-58.
19. Sekine I, Yamada K, Nokihara H, et al (2007). Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renaltoxicity. Can-cer Sci, 98(9):1408-12.
20. Nagai N, Ogata H (1996). The renal clear-ance of unchanged cisplatin during furo-semide and mannitol diuresis is depend-ent on glomerular filtration rate in rats. J Pharm Sci, 85(7):720-4.
21. McMurtry RJ, Mitchell JR (1977). Re-nal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine. Toxicol Appl Pharmacol, 42(2):285-300.
22. Lehane D, Winston A, Gray R et al (1979). The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys, 5(8):1393-9.
23. Clemens E, de Vries AC, Pluijm SF et al (2016). Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Eur J Cancer, 69:77-85.
24. McAlpine D, Johnstone BM (1990). The ototoxic mechanism of cisplatin. Hear Res, 47(3):191-203.
25. Li Y, Ding D, Jiang H, et al (2011). Coad-ministration of cisplatin and furosemide causes rapid and massive loss of cochlear hair cells in mice. Neurotox Res, 20(4):307-19.
26. Muraki K, Koyama R, Honma Y, et al (2012). Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with ad-vanced non-small cell lung cancer. J Thorac Dis, 4(6):562-8.
27. Bodnar L, Wcislo G, Gasowska-Bodnar A, et al (2008). Renal protection with magne-sium subcarbonate and magnesium sul-phate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chem-otherapy: a randomised phase II study. Eur J Cancer, 44(17):2608-14.
28. Kawazoe H, Yano A, Ishida Y, et al (2017). Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study. PLoS One, 12(2): e0171066.
29. Sakata Y, Iwamoto Y, Inata J, et al (2012). Adverse events during pemetrexed ad-ministration caused by concomitant non-steroid anti-inflammatory therapy. Gan To Kagaku Ryoho, 39(6):927-32.
30. van Leeuwen RW, van Gelder T, Mathijssen RH, et al (2014). Drug–drug interactions with tyrosine kinase inhibitors: a clinical perspective. Lancet Oncol, 15(8):e315-26.
31. Chu MP, Ghosh S, Chambers CR, et al (2015). Gastric Acid suppression is asso-ciated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Can-cer, 16 (1):33-9.
32. ter Heine R, van den Bosch RT, Schaefer-Prokop CM, et al (2012). Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung Cancer, 75(3):391-7.
33. Rompelman FM, Smit AA, Franssen EJ, et al (2017). Drug-drug interactions of cyto-statics with regular medicines in lung can-cer patients. J Oncol Pharm Pract, 23(7):483-490.
34. Hadjibabaie M, Badri S, Ataei S, et al (2013). Potential drug-drug interactions at a refer-ral hematology-oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol, 71(6):1619-27.
35. Cruciol-Souza JM, Thomson JC (2006). Prevalence of potential drug-drug interac-tions and its associated factors in a Bra-zilian teaching hospital. J Pharm Pharm Sci, 9(3):427-33.
36. Nobili A, Pasina L, Tettamanti M, et al (2009). Potentially severe drug interactions in elderly outpatients: results of an obser-vational study of an administrative pre-scription database. J Clin Phar Ther, 34(4):377-86.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.